Overview
Balance Sheet
Cash Flow
Growth Analysis
2023
2022
2021
2020
2019
Profitability Metrics
Gross Margin
37.26%
Operating Margin
20.20%
Net Margin
10.57%
Efficiency Metrics
Revenue per Expense Ratio
1.25
R&D as % of Revenue
0.00%
Earnings Quality
EBITDA Margin
43.45%
Income Tax Rate
22.37%
EPS
12.1800000000
Balance Sheet Analysis
Current Ratio
1.44
Cash Ratio
0.14
Working Capital
$224.00M
Debt to Equity
3.52
Debt to Assets
63.43%
Equity Ratio
18.03%
Cash Flow Analysis
Operating Cash Flow Ratio
33.09%
Free Cash Flow Ratio
-11.88%
CapEx to Revenue
44.97%
Dividends Paid
$73.00M
Stock Buybacks
$145.00M
Total Shareholder Returns
$218.00M
Cash Position Change
32.71%
Key Takeaways (2023 FY)
Maintained positive net income growth despite revenue changes
Increased dividend payments by 11.33%
Detailed Growth Metrics
Core Performance
Revenue
19.83%
Net Income
5.15%
EPS
9.24%
Operating Income
18.63%
Operational Efficiency
R&D Expenses
0.00%
SG&A Expenses
9.24%
Operating Cash Flow
18.47%
Free Cash Flow
-9.70%
Balance Sheet Health
Assets
18.54%
Debt
23.89%
Book Value per Share
19.25%
Inventory
0.00%
Shareholder Returns
Dividends per Share
11.33%
Shares Outstanding
-3.72%
Long Term Trends
3Y Revenue/Share
88.13%
5Y Revenue/Share
65.45%
3Y Dividend/Share
0.00%
5Y Dividend/Share
0.00%